| Title |
|
Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
| Type of document |
|
| OrcId |
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
#PLACEHOLDER_PARENT_METADATA_VALUE# |
|
|
| DOI |
|
| Abstract |
|
Aromatase inhibitor (AI) therapy provides oncological benefits in postmenopausal women with oestrogen receptor-positive breast cancer. However, AI treatment has been associated with increased cardiovascular risk. In nonbreast cancer populations, experimentally induced low oestrogen states and natural transition to menopause have been associated with increases in visceral adipose tissue (VAT), a known surrogate marker for cardiometabolic risk. Given that AI treatment blocks oestradiol production, we hypothesized that AI treatment would increase VAT. |
|
|
| Link |
|
| Citation |
|
Clinical endocrinology 2023; 98(2) |
|
|
| Jornal Title |
|
| ISSN |
|
